Enterprise Value

-98.44M

Cash

286.6M

Avg Qtr Burn

-21.87M

Short % of Float

16.84%

Insider Ownership

1.25%

Institutional Own.

97.41%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XMT-1660 (B7-H4 ADC) Details
Ovarian cancer, Cancer, Breast cancer, Endometrial cancer

Phase 1

Data readout

XMT-2056 (HER2 ADC) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

XMT-1592 (NaPi2b antigen) Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Failed

Discontinued